Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SPRY with free AI briefings, catalyst countdowns, and dilution alerts.

SPRY · ARS Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$138.4M Cash on Hand
8.8mo Cash Runway
27.2% Short Interest
$17 Analyst Target (3)
Follow SPRY by email Get an email when SPRY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SPRY, unsubscribe in one click. Privacy

📣 What SPRY Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Epinephrine
FDA approved Aug 2024 · Neffy
Allergic Reactions Phase 4 · NCT06834165 Recruiting
Albuterol MDI 90 mcg/inh Asthma Phase 2 · NCT05363670 Completed
ARS-1 Urticaria Phase 2 · NCT05496465 Completed
ARS-1 without URTI Upper Respiratory Tract Infection Phase 1 · NCT04930900 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SPRY holds $138.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $47.3M/quarter from operations, an estimated runway of 8.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SPRY files for a raise →

👥 Who Owns SPRY

Insiders 36.8% Institutions (262 holders) 63.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
Sarina Tanimoto
CHIEF MEDICAL OFFICER, 10% owner · +1.12M options
Insider 11,353,141 11.29% 2025-08-19
Richard E Lowenthal
PRESIDENT AND CEO, Director, 10% owner · +1.12M options
Insider 11,303,141 11.24% 2025-08-21
RA Capital Management, L.P. Institution (13G, 5%+) 10,940,977 10.88% 2025-09-29
James E Flynn
10% owner
Insider 9,774,508 9.72% 2025-06-27
Orbimed Advisors LLC. Institution (13F) 8,288,510 8.24% 2026-09-30
Rubric Capital Management LP Institution (13G, 5%+) 8,000,000 7.96% 2026-03-31
Deerfield Management Company, L.P. Institution (13G, 5%+) 7,610,217 7.57% 2025-07-30
BlackRock, Inc. Institution (13G, 5%+) 5,218,264 5.19% 2026-06-30
Pratik Shah
Director · +60,000 options
Insider 4,474,554 4.45% 2025-11-12
SR One Capital Management, LP Institution (13F) 4,012,903 3.99% 2026-09-30
State Street Corporation Institution (13F) 3,688,580 3.67% 2026-09-30
UBS Group AG Institution (13F) 3,664,909 3.65% 2026-09-30

Share count 100,528,400 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-02
filed 2026-11-04
Slebir John L
Option award (A) 1,199,482 – –
2026-10-01
filed 2026-10-05
Casale Donn
Option award (A) 1,036,923 – –
2026-09-01
filed 2026-09-02
Smith Margaret Ekins
Option award (A) 1,001,738 – –
2026-07-01
filed 2026-07-02
Casale Donn
Option award (A) 898,456 – –
2026-06-24
filed 2026-06-26
Islam Saqib
Option award (A) 30,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full SPRY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SPRY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.